Elite Athletes Diagnosed and Treated for Diabetes May Reduce Heart Failure

Published Date: 08 Mar 2023

95% of athletes are diagnosed and treated for non-invasive heart disease, such as heart attacks or seizures, or implantable cardioverter defibrillator (ICD) shock.

Read Full News

Latest News

BEACON: Positive Results Announced for Briquilimab in Chronic Spontaneous Urticaria

BEACON: Positive Results Announced for Briquilimab in Chronic Spontaneous Urticaria

Family Quality of Life Burden in CSU Increased by Lack of Disease Control

Family Quality of Life Burden in CSU Increased by Lack of Disease Control

Upadacitinib Superior to 4 Other JAKi Monotherapies for Atopic Dermatitis

Upadacitinib Superior to 4 Other JAKi Monotherapies for Atopic Dermatitis

Q4 2025 Recap: Dermatology News and Updates

Q4 2025 Recap: Dermatology News and Updates

Racial Disparities in Persistent Chemotherapy-Induced Alopecia Observed in Women

Racial Disparities in Persistent Chemotherapy-Induced Alopecia Observed in Women

6 Dermatology Headlines You Missed in December 2025

6 Dermatology Headlines You Missed in December 2025

Todays Updates

Episode 158: Bexicaserin, the PACIFIC Trial, and Treating Developmental Epileptic Encephalopathies Marco Meglio, Johannes Streffer, MD

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Johannes Streffer, MD. [LISTEN TIME: 14 minutes]

BMB-101 Heads for Registrational Trials Following Positive Phase 2 Data in Absence Seizures, Developmental Encephalopathies Marco Meglio

Bright Mind Biosciences reveals promising results for BMB-101 in treating drug-resistant seizures, paving the way for future clinical trials.

Key Neurology Trial Readouts to Watch in Early 2026 Isabella Ciccone, MPH

Review upcoming clinical trials with data readouts expected in the first half of 2026, providing updates relevant to ongoing research and clinical practice in neurology.

5 Rheumatology Headlines You Missed in December 2025

5 Rheumatology Headlines You Missed in December 2025

Diabetes, Anuria May Predict High Postvoid Residual After Kidney Transplantation

Diabetes, Anuria May Predict High Postvoid Residual After Kidney Transplantation

Todays Updates

Episode 158: Bexicaserin, the PACIFIC Trial, and Treating Developmental Epileptic Encephalopathies Marco Meglio, Johannes Streffer, MD

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Johannes Streffer, MD. [LISTEN TIME: 14 minutes]

BMB-101 Heads for Registrational Trials Following Positive Phase 2 Data in Absence Seizures, Developmental Encephalopathies Marco Meglio

Bright Mind Biosciences reveals promising results for BMB-101 in treating drug-resistant seizures, paving the way for future clinical trials.

Key Neurology Trial Readouts to Watch in Early 2026 Isabella Ciccone, MPH

Review upcoming clinical trials with data readouts expected in the first half of 2026, providing updates relevant to ongoing research and clinical practice in neurology.

5 Rheumatology Headlines You Missed in December 2025

5 Rheumatology Headlines You Missed in December 2025

Diabetes, Anuria May Predict High Postvoid Residual After Kidney Transplantation

Diabetes, Anuria May Predict High Postvoid Residual After Kidney Transplantation

Latest News

BEACON: Positive Results Announced for Briquilimab in Chronic Spontaneous Urticaria

Family Quality of Life Burden in CSU Increased by Lack of Disease Control

Upadacitinib Superior to 4 Other JAKi Monotherapies for Atopic Dermatitis

Q4 2025 Recap: Dermatology News and Updates

Racial Disparities in Persistent Chemotherapy-Induced Alopecia Observed in Women

6 Dermatology Headlines You Missed in December 2025

News All Time

Nemolizumab Rapidly Relieves Itch in Atopic Dermatitis, Prurigo Nodularis

Nemolizumab Rapidly Relieves Itch in Atopic Dermatitis, Prurigo Nodularis

Phase 3 SCALP Study on Clascoterone for Androgenetic Alopecia, With Maria Hordinsky, MD

Phase 3 SCALP Study on Clascoterone for Androgenetic Alopecia, With Maria Hordinsky, MD

Vixarelimab Demonstrates Rapid, Sustained Clinical Benefits in Prurigo Nodularis

Vixarelimab Demonstrates Rapid, Sustained Clinical Benefits in Prurigo Nodularis

Once-Daily Oral Zasocitinib Delivers Strong Phase 3 Efficacy in Plaque Psoriasis

Once-Daily Oral Zasocitinib Delivers Strong Phase 3 Efficacy in Plaque Psoriasis

REZOLVE-AA: Phase 2b Data Released on Rezpegaldesleukin for Alopecia Areata

REZOLVE-AA: Phase 2b Data Released on Rezpegaldesleukin for Alopecia Areata

Special Report: Reframing Skin Pain in Atopic Dermatitis Mona Shahriari, MD, FAAD, Andrew Mastro, MS, PA-C

This video explores skin pain as a key symptom of atopic dermatitis and reviews clinical trial data with JAK inhibitors.

Skin of Color Savvy: Winter Skin Care for Patients of Color, With Heather Woolery-Lloyd, MD, and Aderonke Obayomi, MD, MPH

Skin of Color Savvy: Winter Skin Care for Patients of Color, With Heather Woolery-Lloyd, MD, and Aderonke Obayomi, MD, MPH

Addictive Behaviors Linked with Chronic Skin Diseases Such as HS, Psoriasis

Addictive Behaviors Linked with Chronic Skin Diseases Such as HS, Psoriasis

Prurigo Nodularis Linked to Increased Risk of Malignancy, Especially Skin Cancers

Prurigo Nodularis Linked to Increased Risk of Malignancy, Especially Skin Cancers

Imsidolimab’s Biologics License Application for Treatment of GPP Submitted to FDA

Imsidolimab’s Biologics License Application for Treatment of GPP Submitted to FDA

Dupilumab Shows Greatest Rate of 2-Year Drug Survival Among Atopic Dermatitis Drugs

Dupilumab Shows Greatest Rate of 2-Year Drug Survival Among Atopic Dermatitis Drugs

Tips on Patient Communication in Dermatology, With Kassandra Holzem, MD Kassandra Holzem, MD

Holzem spoke in this interview about several additional highlights from her session at SDPA Fall regarding red flags in dermatology and when to admit from the clinic.

Key Skin Cancer Terms Not Understood by Almost 1/3 of Patients Surveyed

Key Skin Cancer Terms Not Understood by Almost 1/3 of Patients Surveyed

FDA Proposes Expanding Active Ingredient List for Sunscreens

FDA Proposes Expanding Active Ingredient List for Sunscreens

Apremilast Effective Treatment for Moderate to Severe Genital Psoriasis at 32 Weeks

Apremilast Effective Treatment for Moderate to Severe Genital Psoriasis at 32 Weeks

Mild to Moderate Psoriasis Linked with Indicators of Suboptimal Treatment, Disease Control

Mild to Moderate Psoriasis Linked with Indicators of Suboptimal Treatment, Disease Control

Recommended News For You

For older LBCL patients, Axi-Cel exhibits durable responses and extends overall survival.

Study: Pre-operative THP leads to pCR in 64% of early-stage HER2+ ER- breast cancer patients

Cancerous breast tissue glows in new AI-enhanced MRI images

CAR-T cell therapy for cancer causes 'brain fog,' study shows

A promising medication could slow brain tumors in children.

Gene Therapy for Hemophilia B Significantly Outperforms Factor IX Prophylaxis

Biomarker panel offers hope for early pancreatic cancer detection

Recommended Articles For You

Biomimetic Nanovesicles Target Senescent-Escape Cancer Stem Cells in Breast Cancer 

Cardio-Oncology: Managing Heart Failure in Survivors of Cancer 

Liquid Biopsy: Revolutionizing Precision Oncology in Hematological Malignancies 

Understanding Dasatinib: A Promising Drug for Cancer Treatment  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

ALK-positive lung cancer trial results show unprecedented progression-free survival.

2.

The way that miR-377 inhibits cells that cause prostate cancer.

3.

More Support for Early Detection; Cancer in Men Rising; Diet Drives Colon Cancer

4.

Pharyngoesophageal junction cancer is not a good candidate for endoscopically assisted transoral surgery.

5.

Annual whole-body, low-dose CT aids management of smoldering multiple myeloma

1.

Precision Oncology Advances: Neoantigen Therapies, TCR Strategies & Radiotherapy Innovations

2.

A New Hope: How Procarbazine is Revolutionizing Cancer Treatment

3.

Cardiotoxicity Beyond Anthracyclines: Redefining Risk in the Cardio-Oncology Era

4.

The Benefits and Risks of Transurethral Resection of Bladder Tumor 

5.

Macrocytic Anemia: A Comprehensive Review of Pathophysiology, Diagnosis, and Clinical Management

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II

2.

From Relapse to Remission : Chasing the Invisible and Redefining Long-Term Survival in Adult R/R B-Cell ALL

3.

Virtual Case Study on Deep Vein Thrombosis (DVT) - An Initiative by Hidoc Dr.

4.

Navigating the Complexities of Ph Negative ALL - Part VIII

5.

Learning About Different Treatment Approaches For Acute Lymphoblastic Leukemia

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot